Research programme: T-cell therapies - Adaptimmune

Drug Profile

Research programme: T-cell therapies - Adaptimmune

Alternative Names: Affinity-enhanced T-cell receptors - Adaptimmune; AFP SPEAR T-cell therapy; AFP TCR - Adaptimmune; AFP-targeted T-cell therapies; Allogenic T-cell therapies - Adaptimmune; Alpha fetoprotein-targeted T-cell therapies; Autologous genetically modified T-cells - Adaptimmune; Cytotoxic T-lymphocytes stimulants - Adaptimmune; MAGE-A4 SPEAR T-cell therapy; PRAME; Preferentially expressed antigen in melanoma

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator Adaptimmune
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Hepatocellular carcinoma; Non-small cell lung cancer
  • Research Diabetes mellitus; Hepatitis C; Immunological disorders; Liver cancer

Most Recent Events

  • 13 Mar 2017 Adaptimmune Therapeutics files for patent protection with patent co-operation treaty for AFP SPEAR T-cell therapy before March 2017
  • 13 Mar 2017 Adaptimmune Therapeutics has patents pending for MAGE-A4 SPEAR T-cell therapy and AFP SPEAR T-cell therapy in United Kingdom
  • 09 Jan 2017 US FDA approves IND application for MAGE-A4 SPEAR T-cell therapy in Solid tumours (malignant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top